A Phase 3b/4, Multicenter, Randomized, Assessor Blinded, Vehicle and Active (Topical Corticosteroid and Calcineurin Inhibitor) Controlled, Parallel Group Study of the Efficacy, Safety, and Local Tolerability of Crisaborole Ointment, 2% in Pediatric and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis